LabGenius Therapeutics Email Format

Biotechnology ResearchEngland, United Kingdom51-200 Employees

LabGenius Therapeutics is a London-based biotechnology research company focused on drug discovery, with a portfolio centered on next-generation therapeutic antibodies. The company operates the EVA™ discovery platform, which combines artificial intelligence, robotic automation, and synthetic biology to accelerate antibody discovery across modalities and formats. Its internal pipeline emphasizes selectivity-enhanced antibodies for solid tumors, aiming to deliver therapeutics with strong tumor-killing profiles. LabGenius has publicly announced preclinical data for LGTX-101, a selectivity-enhanced Nectin-4 x CD3 T-cell engager, with presentations planned at AACR 2026. The company maintains collaborations with Sanofi and LG Chem on ai/ml-designed tumour-targeting antibodies, and is headquartered at 100 Drummond Road, London, England, United Kingdom, with a team of 51-200 employees.

Sign up for free to view info

Company overview Employee directory